Study of N-Acetylcysteine for Treatment of Overt Diabetic Nephropathy
Overview
- Phase
- Phase 2
- Intervention
- N-acetylcysteine
- Conditions
- Diabetic Nephropathy
- Sponsor
- Shiraz University of Medical Sciences
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Proteinuria
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
Diabetic nephropathy has become the single most frequent cause of end-stage renal disease.
On a molecular level, at least five major pathways have been implicated in glucose-mediated vascular and renal damage and all of these could reflect a single hyperglycaemia-induced process of overproduction of reactive oxygen species.
Recent studies have shown that inflammation, and more specifically pro-inflammatory cytokines play a determinant role in the development of micro- vascular diabetic complications, most of the attention has been focused on the implications of TNF-α in the setting of diabetic nephropathy.
Glutathione is the most abundant low-molecular-weight thiol, and Glutathione/ glutathione disulfide is the major redox couple in animal cells.
N-acetylcysteine is effective precursors of cysteine for tissue Glutathione synthesis.
Not only does N-acetylcysteine exhibit antioxidant properties, but it may also counteract the glycation cascade through the inhibition of oxidation.
N-acetylcysteine can also reduce the apoptosis elicited by reactive oxygen species .
Indeed, N-acetylcysteine has been shown to inhibit reactive oxygen species induced mesangial apoptosis and to be able to protect cells from glucose-induced inhibition of proliferation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diabetic patients with more than 500 mg protein in 24 hours urine protein sample
- •Males and post-menopausal non-lactating and non-pregnant females.
- •Age greater than or equal to 30 years of age.
- •Serum creatinine less than 3.0 mg/dL (265 micromoles per liter)
- •Willing and able to give informed consent
Exclusion Criteria
- •Type 1 (insulin-dependent; juvenile onset) diabetes
- •Patients with known non-diabetic renal disease
- •Renal allograft
- •Myocardial infarction, coronary artery bypass graft surgery, or percutaneous transluminal coronary angioplasty/stent within 3 months of study entry
- •Cerebrovascular accident within 3 months of study entry
- •New York Heart Association Functional Class III or IV
- •Known allergies or intolerance to N-acetylcysteine
- •Untreated urinary tract infection or other medical condition that may impact urine protein values.
Arms & Interventions
A, 1,III
in this arm patients took 1200 mg N-acetylcysteine
Intervention: N-acetylcysteine
Outcomes
Primary Outcomes
Proteinuria
Time Frame: 3 months
Secondary Outcomes
- blood pressure,serum creatinine,GFR,c-reactive protein,(3 months)